Long-term protective effect of post-exposure Havrix administration during viral hepatitis Type A outbreaks
Language English Country Netherlands Media print-electronic
Document type Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- MeSH
- Child MeSH
- Adult MeSH
- Disease Outbreaks * MeSH
- Hepatitis A epidemiology prevention & control MeSH
- Immunoglobulins administration & dosage MeSH
- Vaccines, Inactivated MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Hepatitis A Vaccines * MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
- Geographicals
- Slovakia epidemiology MeSH
- Names of Substances
- Immunoglobulins MeSH
- Vaccines, Inactivated MeSH
- Hepatitis A Vaccines * MeSH
Administration of human normal immunoglobulin (HNIG) post-exposure has been routinely used in Slovakia for outbreak control of hepatitis A, but requires deep intramuscular injection, provides only short-lived protection and is a human blood product. The protective effect of post-exposure administration of an inactivated hepatitis A vaccine was evaluated during 10 outbreaks in Slovakia. Direct contacts of confirmed hepatitis A cases received either: a single dose of hepatitis A vaccine (n = 2171) or immunoglobulin (HNIG, n = 3837). In the HNIG group the number of hepatitis A confirmed cases dropped within the first 7 weeks, however the decrease was not as rapid or as marked as that observed in the vaccinated group where the number of hepatitis A cases dropped within the first 4 weeks after vaccination. Among contacts, 67 cases of hepatitis A were detected during the maximum incubation period of 45 days: 16 cases (0.7%) in the vaccine group and 51 cases (1.3%) in the HNIG group (p < 0.05). After two and three years respectively, 50 and 39 volunteers who had previously received one dose of hepatitis A vaccine received a booster dose and anti-HAV antibodies were measured. Differences in anti-HAV antibody GMCs before and after the booster were statistically significant. The longer time interval (3 years instead of 2) between primary vaccination and booster administration did not seem to impact the magnitude of the booster response. The results of this study show that active post-exposure immunisation with only one dose of inactivated vaccine confers high and long-term protection and effectively controls viral hepatitis A outbreaks.
See more in PubMed
Expert Rev Vaccines. 2005 Aug;4(4):459-71 PubMed
Commun Dis Public Health. 1999 Sep;2(3):184-7 PubMed
Commun Dis Public Health. 2001 Jun;4(2):139-40 PubMed
MMWR Recomm Rep. 2006 May 19;55(RR-7):1-23 PubMed
Clin Infect Dis. 1992 Feb;14(2):580-6 PubMed
Lancet. 1999 Apr 3;353(9159):1136-9 PubMed
Arch Pediatr Adolesc Med. 1996 Jul;150(7):733-9 PubMed
J Infect Dis. 1994 Jan;169(1):228-9 PubMed
Lancet. 1993 Apr 10;341(8850):972 PubMed
Vaccine. 2006 Jul 17;24(29-30):5684-9 PubMed
N Engl J Med. 1992 Aug 13;327(7):453-7 PubMed
N Engl J Med. 2005 Sep 1;353(9):890-7 PubMed
J Med Virol. 1994 Dec;44(4):457-9 PubMed
Int J Antimicrob Agents. 2003 Feb;21(2):143-52 PubMed
Vaccine. 2003 Jun 2;21(19-20):2234-7 PubMed
Clinical and laboratory features of viral hepatitis A in children
